Literature DB >> 32699884

Vancomycin-resistant Enterococcus faecium colonizing patients on hospital admission in Germany: prevalence and molecular epidemiology.

Kyriaki Xanthopoulou1,2, Silke Peter1,3, David Tobys1,2, Michael Behnke1,4, Ariane G Dinkelacker1,3, Simone Eisenbeis1,5, Jane Falgenhauer1,6, Linda Falgenhauer1,7, Moritz Fritzenwanker1,6, Hannah Gölz1,8, Georg Häcker1,8, Paul G Higgins1,2, Can Imirzalioglu1,6, Nadja Käding1,9, Winfried V Kern10, Evelyn Kramme1,9, Axel Kola1,4, Alexander Mischnik1,9, Siegbert Rieg1,10, Anna M Rohde1,4, Jan Rupp1,9, Evelina Tacconelli1,5, Maria J G T Vehreschild1,11,12, Sarah V Walker1,2, Petra Gastmeier1,4, Harald Seifert1,2.   

Abstract

OBJECTIVES: To analyse the rectal carriage rate and the molecular epidemiology of vancomycin-resistant Enterococcus faecium (VREfm) recovered from patients upon hospital admission.
METHODS: Adult patients were screened at six German university hospitals from five different federal states upon hospital admission for rectal colonization with VREfm between 2014 and 2018. Molecular characterization of VREfm was performed by WGS followed by MLST and core-genome MLST analysis.
RESULTS: Of 16350 patients recruited, 263 were colonized with VREfm, with increasing prevalence rates during the 5 year study period (from 0.8% to 2.6%). In total, 78.5% of the VREfm were vanB positive and 20.2% vanA positive, while 1.2% harboured both vanA and vanB. The predominant ST was ST117 (56.7%) followed by ST80 (15%), ST203 (10.9%), ST78 (5.7%) and ST17 (3.2%). ST117/vanB VREfm isolates formed a large cluster of 96 closely related isolates extending across all six study centres and four smaller clusters comprising 13, 5, 4 and 3 isolates each. In contrast, among the other STs inter-regional clonal relatedness was rarely observed.
CONCLUSIONS: To our knowledge, this is the largest admission prevalence and molecular epidemiology study of VREfm. These data provide insight into the epidemiology of VREfm at six German university hospitals and demonstrate the remarkable inter-regional clonal expansion of the ST117/vanB VREfm clone.
© The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32699884     DOI: 10.1093/jac/dkaa271

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  5 in total

1.  Genomic Surveillance of Vancomycin-Resistant Enterococcus faecium Reveals Spread of a Linear Plasmid Conferring a Nutrient Utilization Advantage.

Authors:  Mathilde Boumasmoud; Vanina Dengler Haunreiter; Tiziano A Schweizer; Lilly Meyer; Bhavya Chakrakodi; Peter W Schreiber; Kati Seidl; Denise Kühnert; Roger D Kouyos; Annelies S Zinkernagel
Journal:  mBio       Date:  2022-03-28       Impact factor: 7.786

Review 2.  Combination of Whole Genome Sequencing and Metagenomics for Microbiological Diagnostics.

Authors:  Srinithi Purushothaman; Marco Meola; Adrian Egli
Journal:  Int J Mol Sci       Date:  2022-08-30       Impact factor: 6.208

3.  The Role of Whole Genome Sequencing in the Surveillance of Antimicrobial Resistant Enterococcus spp.: A Scoping Review.

Authors:  Lindsay A Rogers; Kayla Strong; Susan C Cork; Tim A McAllister; Karen Liljebjelke; Rahat Zaheer; Sylvia L Checkley
Journal:  Front Public Health       Date:  2021-06-10

4.  Molecular Epidemiology of Vancomycin-Resistant Enterococci Bloodstream Infections in Germany: A Population-Based Prospective Longitudinal Study.

Authors:  Carlos L Correa-Martínez; Annette Jurke; Janne Schmitz; Frieder Schaumburg; Stefanie Kampmeier; Alexander Mellmann
Journal:  Microorganisms       Date:  2022-01-08

5.  Epidemiological and genetic characteristics of vancomycin-resistant Enterococcus faecium isolates in a University Children's Hospital in Germany: 2019 to 2020.

Authors:  Ilona Trautmannsberger; Laura Kolberg; Melanie Meyer-Buehn; Johannes Huebner; Guido Werner; Robert Weber; Valerie Heselich; Sebastian Schroepf; Hans-Georg Muench; Ulrich von Both
Journal:  Antimicrob Resist Infect Control       Date:  2022-03-12       Impact factor: 4.887

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.